Aptevo Therapeutics
9
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
33.3%
3 terminated/withdrawn out of 9 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Role: lead
ALG.APV-527 First-in-human Study
Role: lead
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
Role: lead
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Role: lead
Phase 1b Safety and Efficacy Study of TRU-016
Role: lead
Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
Role: lead
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
Role: lead
Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
Role: lead
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Role: lead
All 9 trials loaded